MedTrace Logo

Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma

NCT05316467 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2025-08-11

No results posted yet for this study

Summary

To investigate the efficacy of weight management plus megestrol acetate in obese patients with early endometrioid carcinoma（EEC）asking for fertility-sparing treatment

Conditions

Interventions

BEHAVIORAL

Intensive Lifestyle Intervention (ILI)

* dietary guidance * exercise guidance * lifestyle intervention

DRUG

Megestrol Acetate 160 MG Oral Tablet

enrolled participants will take Megestrol Acetate 160mg daily

Sponsors & Collaborators

  • Xiaojun Chen

    lead OTHER

Principal Investigators

  • XIAOJUN CHEN, PhD · Obstetrics & Gynecology Hospital of Fudan University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2026-02-28
Completion
2027-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05316467 on ClinicalTrials.gov